Loading stock data…
TSHA
$6.33-0.06 (-0.94%)
Market ClosedLast close May 1
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Taysha Gene Therapies, Inc. in the Healthcare sector is trading at $6.33. The stock is currently near its 52-week high of $6.76, remaining 45.2% above its 200-day moving average. Technical signals show overbought RSI of 76 and bullish MACD crossover, explaining why TSHA maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 76) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.33
Potential Upside
5%
Whystock Fair Value$6.65
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company prima...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.87B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-37.55%
Volume
Today's trading volume
1.73M
Recent News
Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?
If you are wondering whether Taysha Gene Therapies at US$6.46 is starting to look expensive or still has room to run, the key question is what the current price implies about the company’s underlying value. The stock has been flat over the last week, while the 30 day return is 58.7%, the year to date return is 23.0% and the 1 year return is 258.9%, with a very large 3 year return and a 72.6% decline over 5 years highlighting how quickly sentiment can shift. Recent coverage has focused on...
Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock is up 343.45% from its price a year ago and 22.48% year-to-date. On April 15, Needham reiterated its buy rating for Taysha Gene Therapies with a price target of $12. Earlier on April 6, Canaccord […]
This is Why Taysha Gene Therapies, Inc. (TSHA) is one of the Best Healthcare Penny Stocks to Buy
Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best healthcare penny stocks to buy according to hedge funds. On April 6, Canaccord reiterated its Buy rating on Taysha Gene Therapies Inc. (NASDAQ:TSHA) and raised its price target to $17 from $14. The price target hike comes on the heels of the stock’s impressive 258% return […]
Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best multibagger penny stocks to invest in. On March 25, Cantor Fitzgerald reiterated an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) with a $19 price target. The positive stance is in response to the company making significant progress on the development of TSHA-102, an investigational gene […]
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline.